Patients in the Micra Coverage with Evidence Development (CED) study treated with Medtronic PLC's Micra TPS leadless pacemaker have a lower risk of chronic complications six months after implant than patients treated with a traditional single-chamber pacemaker with transvenous leads.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?